Compare Nebius Group NV (NBIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs State Street SPDR S&P Biotech ETF — how do they compare? Nebius Group NV trades at $234 (market cap $65.34B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| NBIS | XBI | |
|---|---|---|
Market Cap | $65.34B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $286.69 | $169.55 |
52-Week Low | $73.87 | $93.43 |
Enterprise Value | $67.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS stock trades at $243.88, up 7.73% on the day, driven by a strategic partnership with Palantir for sovereign AI infrastructure, as reported by Benzinga on September 8, 2026. The stock shows bullish technical signals with strong moving average support and a consensus analyst price target of $300.43. Revenue growth is projected to surge from $530 million in 2025 to $1.4 billion in 2026, though net income margins are thin at 3.13%.
The outlook is positive due to high AI demand and analyst optimism, with 80% buy ratings. Risks include elevated valuation multiples, such as a P/E of 74.61, and execution challenges in scaling infrastructure. Investors should weigh growth potential against profitability concerns and market volatility.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
